Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Simon Sturge Insider Profile
4 Followers
Simon Sturge, Director at MoonLake Immunotherapeutics, holds 171.98K shares in MoonLake Immunotherapeutics (Ticker: MLTX). Most recently, Simon Sturge Sold $171,000 shares of MoonLake Immunotherapeutics on Oct 08, 2024 for an estimated value of 9.19M.
Simon Sturge has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Simon Sturge holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Oct 08, 2024 - Today
Return:-3.80%
The most profitable trade made by Simon Sturge
Simon Sturge's Trading History
List of latest transactions for each holding click on a transaction to see Simon Sturge's performance on stock
You May Also Like
Simon Sturge insider profile FAQ
What is the percentage of profitable transactions made by Simon Sturge?
The percentage of profitable transactions made by Simon Sturge is ―.
What is the average return per transaction made by Simon Sturge?
The average return per transaction made by Simon Sturge is ―.
What stocks does Simon Sturge hold?
Simon Sturge holds: MLTX stocks.
What was Simon Sturge’s latest transaction?
Simon Sturge latest transaction was an Informative Sell of $9.19M.
What was Simon Sturge's most profitable transaction?
Simon Sturge’s most profitable transaction was an Informative Sell of MLTX stock on October 8, 2024. The return on the trade was -3.80%.
What is Simon Sturge's role in MoonLake Immunotherapeutics?
Simon Sturge's role in MoonLake Immunotherapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.